Business Editors and Health Writers

SAN DIEGO, CA   August 31,  1997 - Privately held Structural Bioinformatics Inc. ("SBI") of San Diego, California, has elected three new directors to its Board.  The new directors, Dr. Edgar Engleman, Mr. John Kenward and Dr. Frank Kung, were elected during the August 28th Board Meeting following the successful close of the second round funding.

Dr. Engleman is Professor of Medicine and Pathology of the Stanford University School of Medicine.  He is a co-founder of Cetus Immune and Genelabs Technologies, Inc., National Medical Audit and Activated Cell Therapy Inc.  He is the holder of multiple patents, is credited as the inventor of the first generation AIDS test for use in screening blood donors, and is the discoverer or therapeutic agents for systemic lupus, AIDS, and malignant tumors which are currently in clinical trials.

Mr. Kenward served formerly as CEO of Ixsys Inc, COO of RepliGen Corporation, and Senior Vice President of Marketing, Medical and Scientific Operations for the Schering-Plough Corporation.   Mr. Kenward has over 25 years experience in the pharmaceutical and biotechnology industries in the United States and Europe.  Mr. Kenward obtained his M.A. degree in Chemistry from Oxford University, United Kingdom.

Dr. Kung has been working in the biotechnology industry since its inception when he joined the Cetus Corporation in 1979. He has earned the Best Use of Technology Award from the Governor of the State of California, the Entrepreneur of the Year Award from Ernst & Young, and the Entrepreneur of the Year Award from the Asian Business League. Currently, Dr. Kung serves as a member of the Board of Directors of a number of other companies and biotechnology organizations.

Structural Bioinformatics has developed a supercomputational operating system making possible the immediate and practical use of genomic (gene sequence) data in a broad range of structure-based drug discovery and design processes leading to the rapid design and identification of small molecule lead compounds.  SBI is building corporate partnerships with pharmaceutical companies, gene discovery companies, and combinatorial chemistry companies ranging from broad technology collaborations to assistance with specific drug targets or target groups.